First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: A quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale
Vittorio Gebbia(Università degli Studi di Enna Kore), Giuseppe Colucci(University of Basel), Giuseppe Palomba, Domenico Galetta(Istituto Tumori Bari), Gianfranco Mancuso, S. Mancarella(Radiation Oncology Institute), Francesco Carrozza(Ospedale per gli Infermi), Francesco Ferraù(Université Paris-Sud), Michele Caruso M, Nicolò Borsellino(Ospedale Buccheri la Ferla Fatebenefratelli), Silvana Leo(Ospedale Vito Fazzi), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Vito Lorusso(Ospedale Vito Fazzi), Saverio Cinieri(Ospedale A. Perrino)
Cited by 18
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial
|JNCI Journal of the National Cancer Institute|2003|795
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2019|617
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240